Author:
Lyseng-Williamson Katherine A.
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. National Comprehensive Cancer Network®. Clinical Practice Guidelines in Oncology (NCCN Guidelines®): kidney cancer (version 4.2018). Fort Washington: National Comprehensive Cancer Network®, Inc.; 2018.
2. Garcia-Roig M, Ortiz N, Lokeshwar V. Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need? Curr Urol Rep. 2014;15:375.
3. Tannir NM, Schwab G, Grunwald V. Cabozantinib: an active novel multikinase inhibitor in renal cell carcinoma. Curr Oncol Rep. 2017;19(2):14.
4. Yu SS, Quinn DI, Dorff TB. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther. 2016;9:5825–37.
5. Gill DM, Hahn AW, Hale P, et al. Overview of current and future first-line systemic therapy for metastatic clear cell renal cell carcinoma. Curr Treat Options Oncol. 2018;19(1):6.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献